Skip to main content
Log in

Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT

  • Brief Article
  • Published:
Molecular Imaging and Biology Aims and scope Submit manuscript

Abstract

Purpose

2-Deoxy-2-[F-18]fluoro-d-glucose (FDG)-positron emission tomography (PET) has an established role in restaging of various cancers, including papillary and undifferentiated thyroid carcinoma. However, controversies exist regarding its ability to reliably assess recurrent medullary thyroid cancer (MTC). We were therefore prompted to review our experience with FDG-PET for detection of occult MTC.

Methods

This is a retrospective study (Apr 1, 1997–Mar 31, 2004) of 13 patients with histologic diagnosis of MTC, who had PET examinations. The group included six men and seven women, 15–62 years old (average: 48 ± 13). The PET scan request was triggered by rising levels of calcitonin and negative anatomical imaging studies.

Results

Recurrent/metastatic disease was identified by PET in seven (54%) of the 13 patients. The lesions were located in superior mediastinum (4), cervical lymph nodes (3), thyroid bed (2), lung (1) and liver (1). The calcitonin levels ranged from 52 to 5,090 pg/ml (average: 1,996 pg/ml) in patients with negative PET scans and from 132 to 9,500 pg/ml (average: 3,757 pg/ml) in patients with positive studies. The sensitivity and specificity of FDG-PET for disease detection in this cohort were 85.7% (95% CI: 48.7–97.4) and 83.3 % (95 % CI: 43.6–96.9), respectively.

Conclusion

Our findings suggest a significant role for FDG-PET in patients with suspected MTC recurrence, with sensitivity of 85.7% and specificity of 83.3% for disease detection. FDG-PET provides additional information in a significant fraction of cases (54%) and could be used for restaging of patients with MTC and elevated levels of biomarkers (calcitonin). Additional studies are necessary to further evaluate the role of FDG-PET in MTC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel A, Ward E, Murray T, Xu J, Smigal C, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130 (Mar–Apr)

    PubMed  Google Scholar 

  2. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428 (Nov)

    Article  PubMed  CAS  Google Scholar 

  3. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS (1993) Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery 114:1050–1057 (Dec)

    PubMed  CAS  Google Scholar 

  4. O’Riordain DS, O’Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, et al. (1994) Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 116:1017–1023 (Dec)

    PubMed  CAS  Google Scholar 

  5. Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d’etude des tumeurs a calcitonine. Clin Endocrinol (Oxf) 48:265–273 (Mar)

    Article  CAS  Google Scholar 

  6. Musholt TJ, Musholt PB, Dehdashti F, Moley JF (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery 122:1049–1060; discussion 1060–1061 (Dec)

    Article  PubMed  CAS  Google Scholar 

  7. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797–804 (Aug)

    Article  PubMed  CAS  Google Scholar 

  8. Conti PS, Lilien DL, Hawley K, Keppler J, Grafton ST, Bading JR (1996) PET and [18F]-FDG in oncology: a clinical update. Nucl Med Biol 23:717–735 (Aug)

    Article  PubMed  CAS  Google Scholar 

  9. Gasparoni P, Rubello D, Ferlin G (1997) Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 20:527–530 (Oct)

    PubMed  CAS  Google Scholar 

  10. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L (2000) Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 25:273–282 (Apr–Jun)

    PubMed  CAS  Google Scholar 

  11. de Groot JW, Links TP, Jager PL, Kahraman T, Plukker JT (2004) Impact of 18F-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786–794 (Aug)

    Article  PubMed  Google Scholar 

  12. Adalet I, Kocak M, Oguz H, Alagol F, Cantez S (1999) Determination of medullary thyroid carcinoma metastases by 201Tl, 99Tcm(V)DMSA, 99Tcm-MIBI and 99Tcm-tetrofosmin. Nucl Med Common 20:353–359 (Apr)

    Article  CAS  Google Scholar 

  13. Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N, et al. (1996) Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23:1367–1371 (Oct)

    Article  PubMed  CAS  Google Scholar 

  14. Brandt-Mainz K, Muller SP, Gorges R, Saller B, Bockisch A (2000) The value of F-18 FDG PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490–496 (May)

    Article  PubMed  CAS  Google Scholar 

  15. Crippa F, Alessi A, Gerali A, Bombardieri E (2003) FDG-PET in thyroid cancer. Tumori 89:540–543 (Sep–Oct)

    PubMed  Google Scholar 

  16. Hoegerle S, Altehoefer C, Ghanem N, Brink I, Moser E, Nitzsche E (2001) 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64–71 (Jan)

    Article  PubMed  CAS  Google Scholar 

  17. Diehl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, et al. (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study. Eur J Nucl Med 28:1671–1676 (Nov.)

    Article  PubMed  CAS  Google Scholar 

  18. Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Current Cancer Drug Targets 5:139–148 (Mar)

    Article  PubMed  CAS  Google Scholar 

  19. Gotthardt M, Battmann A, Hoffken H, Schurrat T, Pollum H, Beuter D, et al. (2004) 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun 25:439–443 (May)

    Article  PubMed  CAS  Google Scholar 

  20. Bockisch A, Brandt-Mainz K, Gorges R, Muller S, Stattaus J, Antoch G (2003) Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22–25 (May)

    Article  PubMed  CAS  Google Scholar 

  21. Szakall S Jr, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovics I, et al. (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66–71 (Jan)

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Peter S. Conti MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iagaru, A., Masamed, R., Singer, P.A. et al. Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT. Mol Imaging Biol 9, 72–77 (2007). https://doi.org/10.1007/s11307-006-0072-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11307-006-0072-1

Key words

Navigation